A controlled study of the efficacy and safety of mianserin and maprotiline in outpatients with major depression
by
Moller HJ, Riehl T, Dietzfelbinger T, Wernicke T
Psychiatric Clinic,
University of Bonn,
Venusberg, Germany.
Int Clin Psychopharmacol 1991 Winter; 6(3):179-92

ABSTRACT

Efficacy and tolerability of mianserin (60-90 mg/day) or maprotiline (100-150 mg/day) were tested in a 4-week double-blind control group study on 317 depressive outpatients. The patients had to fulfill the criteria of a major depression according to DSM-III. The study was performed by psychiatrists after special rater training. Standardized rating procedures were applied to evaluate depressive symptoms and unwanted effects at three measurement points. A significant improvement was found in both groups, without any statistical differences between mianserin and maprotiline. According to the Clinical Global Impressions (CGI) 65% of the patients in both groups were judged as responders. A good tolerability of both drugs were demonstrated. With respect to anticholinergic side-effects there was a certain advantage in favor to mianserin.

TCAs
SSRIs
Options
Mianserin
Reboxetine
Amineptine
Dumb drugs
TCAs v SSRIs
Norepinephrine
Antidepressant toxicity
Maprotiline versus paroxetine
Maprotiline versus amitriptiline
Maprotiline versus fluvoxamine
Maprotiline versus moclobemide
Mianserin (Bolvidon) extends lifespan

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family